瑞磁結合半導體 獨創檢測技術

結合半導體的製程，和生物科技的技術，做出全球唯一的數位生物條碼，並且取得美國ＦＤＡ認證通過，瑞磁生技做到台灣廠商沒做到的事情

文／尚清林

四月二十四日，普生盤中大漲七成，金萬林大漲二七％，瑞基、寶齡、台康生紛紛亮燈漲停改寫上市櫃後新高。正當市場上都在找尋下一檔尚未發掘到的「檢測試劑概念股」時，瑞磁生技就發出公告，開發的COVID-19 核酸檢測試劑，已正式向美國 ＦＤＡ（食品藥物管理局） 提出申請。這一消息讓興櫃掛牌的瑞磁生技跟著市場腳步，大漲一八％，股價來到七十七元，一同改寫歷史新高。 只見法人快速估算，瑞磁生技是以緊急使用授權和銷售分發方式向ＦＤＡ申請，預料四月底前可通過審查，五月就可以出貨十萬人份的檢測試劑，營收貢獻將高達七千五百萬元，對於瑞磁而言，絕對是份大禮。 「瑞磁生技？真的可以嗎？有技術嗎？不是海外詐騙集團吧？」這是一般人聽到瑞磁生技的第一印象，特別是看股票代號ABC-KY，還以為是教美語的。這和由中研院掛保證的泰博、普生、台塑生醫等九家台廠，作為快篩合作廠商，兩者之間熟悉度相差很多。 陌生的飆股 端出FDA認證…

You're reading a preview of

Wealth Magazine 財訊雙週刊 (Digital) - 1 Issue, No.606_Apr-30-20

DiscountMags is a licensed distributor (not a publisher) of the above content and Publication through Zinio LLC. Accordingly, we have no editorial control over the Publications. Any opinions, advice, statements, services, offers or other information or content expressed or made available by third parties, including those made in Publications offered on our website, are those of the respective author(s) or publisher(s) and not of DiscountMags. DiscountMags does not guarantee the accuracy, completeness, truthfulness, or usefulness of all or any portion of any publication or any services or offers made by third parties, nor will we be liable for any loss or damage caused by your reliance on information contained in any Publication, or your use of services offered, or your acceptance of any offers made through the Service or the Publications. For content removal requests, please contact Zinio.